Ken Griffin Rani Therapeutics Holdings, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2024 Feb 14, 2025	BUY	$1.3 - $3.18 $1,040 - $2,544	800 Added 32.0%	3,300 $4,000
Q3 2024 Nov 14, 2024	BUY	$2.06 - $3.99 $1,030 - $1,995	500 Added 25.0%	2,500 $5,000
Q2 2024 Aug 14, 2024	SELL	$3.13 - $7.85 $16,902 - $42,390	-5,400 Reduced 72.97%	2,000 $7,000
Q1 2024 May 15, 2024	BUY	$2.98 - $3.8 $22,052 - $28,120	7,400 New	7,400 $23,000
Q2 2023 Aug 14, 2023	BUY	$3.92 - $5.58 $8,624 - $12,276	2,200 Added 220.0%	3,200 $13,000
Q1 2023 May 15, 2023	BUY	$5.07 - $6.89 $5,070 - $6,890	1,000 New	1,000 $5,000

3.68M

44K

193K

Ticker RANI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,492,000
Market Cap $41.1M
Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed P...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.